Filing summary
Entity and period mismatch: The request identifies Newegg Commerce, Inc. and 2012 Q4, but the supplied filing is Dehaier Medical Systems Limited’s Form 10-K for the fiscal year ended December 31, 2012. The figures below summarize the supplied filing, not Newegg’s. The filing reports annual results; standalone fourth-quarter financial results are not clearly provided in the text.
Business context and reporting period
Dehaier develops and distributes medical devices in China, including hospital equipment and respiratory and oxygen homecare products. It sells mainly through distributors and also serves hospitals, government procurement projects and individuals. Most manufacturing is outsourced; the company performs some final assembly. The audited statements cover fiscal 2012 and compare with fiscal 2011. Friedman LLP issued an unmodified opinion on the financial statements.
Financial performance and liquidity
| Metric | FY2012 | FY2011 | Change or context |
|---|---|---|---|
| Revenue | $21.37 million | $21.64 million | Down 1.24% |
| Gross profit / margin | $8.12 million / 37.98% | $7.94 million / 36.70% | Margin improved 1.28 percentage points |
| Operating income | $4.39 million | $3.61 million | Up 21.46% |
| Net income | $3.22 million | $3.13 million | Up 2.88% |
| Net income attributable to Dehaier | $3.21 million | $3.10 million | Basic and diluted EPS: $0.70 vs. $0.69 |
| Cash from operations | $1.70 million provided | $3.16 million used | Improved year over year |
| Cash and cash equivalents, year-end | $3.51 million | $3.69 million | Down $0.19 million |
| Short-term borrowings, year-end | $2.41 million | $1.59 million | Debt is short-term; secured by a building and guaranteed by the subsidiary and an officer |
Operating costs and expenses declined to $17.21 million from $18.20 million. Selling expense fell 27.66%, which management attributed to more focused marketing and lower travel costs. The filing reports working capital of $28.85 million and says available working capital should cover anticipated needs for at least 12 months. Total assets were $38.28 million, total liabilities $4.21 million, and total equity $34.07 million at year-end.
Investing activities used $2.73 million, principally for software copyrights; the cash flow statement reports $2.72 million of software copyright spending. Financing activities provided net cash of $0.79 million. Capital expenditures were reported as approximately $2.73 million, versus $0.15 million in 2011.
Material changes versus the prior year
- Revenue declined slightly as traditional medical-device sales weakened amid competition. Medical-device revenue fell to $18.55 million from $19.36 million, while respiratory and oxygen homecare revenue increased to $2.82 million from $2.28 million.
- Gross margin and operating income improved as cost of revenue and selling expense fell. Management said the revenue mix shift away from traditional devices supported margins and earnings.
- Operating cash flow turned positive, aided by lower accounts receivable and inventory. Increased prepayments and other receivables offset some of that benefit.
- Intangible assets rose from zero to $2.69 million, mainly reflecting software copyrights. Warrants liability increased to $374,166 from $96,469; the fair-value change reduced 2012 income by $180,192, compared with a $221,640 gain in 2011.
- Revenue concentration increased: the three top-selling products represented approximately 68% of revenue in 2012, versus 27% in 2011.
Outlook, risks and notable items
- Management expected opportunities from China’s healthcare investment and aging population, government procurement, and demand for homecare equipment. It described the homecare business as early-stage and said 2013 efforts would focus on product introductions and market penetration rather than significant near-term revenue.
- Plans included expanding government-project participation, distribution relationships, research and development, home oxygen therapy and overseas markets. These are forward-looking statements, not guaranteed results.
- Key disclosed exposures include intense competition, reliance on distributors and international suppliers, third-party manufacturing, and customer and product concentration. Two customers each generated approximately 13% of revenue in both 2012 and 2011. Three suppliers represented approximately 34%, 33% and 19% of payables at year-end 2012.
- The medical-device assembly permit and distribution license were both due to expire on September 15, 2013. The company said renewal applications had not yet been filed but were anticipated soon. Several product registrations also had 2013–2016 expiration dates.
- Short-term loans were secured by BTL’s building; the filing also describes officer guarantees. Subsequent to year-end, the company repaid a $802,400 bank loan and a $481,440 credit-line borrowing, and entered a replacement $802,400 loan due in March 2014.
- The filing states that certain 2008 and 2009 VAT returns for some customers had been filed and potential liabilities accrued, while an earlier MD&A passage says the company was awaiting resolution and had not yet filed those returns. This disclosure is inconsistent and merits clarification.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2012. The auditor did not audit internal control effectiveness. The company did not provide the Item 1A risk-factor discussion because it was a smaller reporting company.
Important facts for investors to verify
- Confirm the intended issuer and period: the supplied document is Dehaier’s FY2012 10-K, not a Newegg filing or a standalone Q4 report.
- Check renewal status and continued validity of the September 2013 assembly permit and distribution license, and the relevant product registrations.
- Review customer, product and supplier concentration, including collectability of receivables, contract deposits and supplier advances.
- Reconcile the VAT-return disclosure and confirm the status and amount of any related tax exposure.
- Verify the timing and terms of post-year-end loan repayments and refinancing, and the collateral and guarantees supporting borrowings.
- Assess whether the higher-margin homecare and government-procurement businesses can offset competitive pressure on traditional device sales.